Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Summit Therapeutics (SMMT) Cash & Current Investments (2018 - 2025)

Summit Therapeutics' Cash & Current Investments history spans 8 years, with the latest figure at $238.6 million for Q3 2025.

  • For Q3 2025, Cash & Current Investments rose 153.52% year-over-year to $238.6 million; the TTM value through Sep 2025 reached $238.6 million, up 153.52%, while the annual FY2024 figure was $105.2 million, 47.27% up from the prior year.
  • Cash & Current Investments reached $238.6 million in Q3 2025 per SMMT's latest filing, down from $298.2 million in the prior quarter.
  • In the past five years, Cash & Current Investments ranged from a high of $648.6 million in Q4 2022 to a low of $28.8 million in Q2 2024.
  • Average Cash & Current Investments over 5 years is $178.7 million, with a median of $105.2 million recorded in 2024.
  • Peak YoY movement for Cash & Current Investments: tumbled 88.99% in 2023, then surged 937.04% in 2025.
  • A 5-year view of Cash & Current Investments shows it stood at $103.4 million in 2021, then soared by 527.28% to $648.6 million in 2022, then crashed by 88.99% to $71.4 million in 2023, then soared by 47.27% to $105.2 million in 2024, then surged by 126.79% to $238.6 million in 2025.
  • Per Business Quant, the three most recent readings for SMMT's Cash & Current Investments are $238.6 million (Q3 2025), $298.2 million (Q2 2025), and $211.8 million (Q1 2025).